December 9, 2013 Synthetic Biologics and Intrexon Corporation Initiate Development of Novel Biologics for a Subset of Patients Suffering from Irritable Bowel Syndrome (IBS)
December 9, 2013 Synthetic Biologics' Webcast Conference Call Set for 9:00 a.m. EST this Morning, December 9th
December 7, 2013 Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes
December 2, 2013 Synthetic Biologics to Present at the LD MICRO VI: Main Event Conference in Los Angeles
November 14, 2013 Synthetic Biologics' SYN-004 for the Prevention of C. difficile Infections Named a "Top Project to Watch" by Elsevier Business Intelligence
